logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

Inside the Revolution In the Treatments of Untreatable Diseases We are now living a great revolution in the treatment of diseases. We expect to discover novel treatments capable of defeating cancers’ resistance to therapeutics old and new. We are following...

Read More

May 26, 2023

0

At 2:30 PM Today the Chairman of the Federal Reserve will Reveal the Decision About Interest Rates. See Also: Good News from Gilead

Today at 2.30... Today at 2.30, the Federal Reserve Chairman Jerome Powell will speak to the United States and the rest of the world about the Fed’s decision with regard to interest rates. Financial analysts in five star financial journals...

Read More

June 14, 2023

0

Vera Therapeutics Announces Positive Week 36 Safety and Efficacy Results in Phase 2b Clinical Trial of Atacicept in IgA Nephropathy

Vera Therapeutics Vera Therapeutics ( VERA ) announced that Phase 2b ORIGIN clinical trial of atacicept for IgA nephropathy  met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR through...

Read More

June 20, 2023

0

The U.S. FDA Approved BioMarin Pharmaceutical's ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical US FDA Approved ROCTAVIAN BioMarin Pharmaceutical ( BMRN ) announced that the U.S. FDA approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 ( AAV5 ) detected by...

Read More

June 30, 2023

0

The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US

BioMarin Pharmaceutical US FDA Approval for ROCTAVIAN On June 30, 2023, BioMarin Pharmaceutical ( BMRN ) announced that the U.S. FDA has approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII ( FVIII )...

Read More

July 6, 2023

0

Treating Cancers Resistant to ALL Drugs a Priority for Researchers. See What Merck and Kintara Have Done

Merck and Kintara in the NEWS Treating cancers that have no treatments should be a priority for researchers to create a treatment for them.  Patients who are afflicted with untreatable deadly diseases might not have a single drop of hope...

Read More

July 20, 2023

0

Halozyme Therapeutics' Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

The way drugs are being delivered into patients’ bodies have become more than ever considered important with regard to the safety and efficacy of the treatments. We consider Halozyme Biopharmaceutical is a leader in bringing disruptive solutions to significantly improve patient...

Read More

July 21, 2023

0

TG Therapeutics Will Have An Important Conference Call at 8:30 AM Tomorrow, August 1st

TG Therapeutics Conference Call TG Therapeutics ( TGTX ) announced that, tomorrow, Tuesday, August 1, 2023, a conference call will be held at 8.30 AM ET, to discuss the results of the second quarter 2023 and provide a business outlook...

Read More

July 31, 2023

0

Xenon Pharmaceuticals Reports 2Q 2023 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals Q2 Financial Results On  August 09, 2023 , Xenon Pharmaceuticals ( XENE ) reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. Xenon report started with Mr. Ian Mortimer, the firm’s President and Chief...

Read More

August 15, 2023

0

The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

Nuvectis Pharma Nuvectis Pharma ( NVCT ) is a biopharmaceutical company focused on developing innovative precision targeted drugs capable of treating cancers that have yet to find treatments. The Company’s pipeline comprises two drug candidates, NXP800 and NXP900. NXP800  is...

Read More

August 20, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 69
  • 70
  • 71
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy